Once there was a clear distinction between the scientific evaluation of new drugs and the assessment of their value for use in reimbursement decisions. The latter was often referred to as the “fourth hurdle” and took place after quality, safety and efficacy had been assessed and the product approved...
Please login to read the full article.
